Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine

US9212183B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Peter Sieger · Mittelbiberach, DE
• Waldemar Pfrengle · Seibersbach, DE

Key dates

• Filing date: May 9, 2014
• Grant date: Dec 15, 2015
• Expiry date: May 9, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C309/29
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, processes for making these novel salts, and pharmaceutical compositions comprising such novel salts. The invention also relates to the use of these novel salts in the treatment of type 2 diabetes.